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Abstract
Background aims. Mesenchymal stromal cells (MSCs) are being extensively researched for cell therapy and tissue engineer-
ing.We have engineered MSCs to express the pro-apoptotic protein tumor necrosis factor–related apoptosis inducing ligand
(TRAIL) and are currently preparing this genetically modified cell therapy for a phase 1/2a clinical trial in patients with
metastatic lung cancer. To do this, we need to prepare a cryopreserved allogeneic MSCTRAIL cell bank for further ex-
pansion before patient delivery.The effects of cryopreservation on a genetically modified cell therapy product have not been
clearly determined. Methods. We tested different concentrations of dimethyl sulfoxide (DMSO) added to the human serum
albumin ZENALB 4.5 and measured post-thaw cell viability, proliferation ability and differentiation characteristics. In ad-
dition, we examined the homing ability, TRAIL expression and cancer cell–killing capacities of cryopreserved genetically
modified MSCs compared with fresh, continually cultured cells. Results. We demonstrated that the post-thaw viability of
MSCs in 5% DMSO (v/v) with 95% ZENALB 4.5 (v/v) is 85.7 ± 0.4%, which is comparable to that in conventional freez-
ing media.We show that cryopreservation does not affect the long-term expression of TRAIL and that cryopreserved TRAIL-
expressing MSCs exhibit similar levels of homing and, importantly, retain their potency in triggering cancer cell death.
Conclusions. This study shows that cryopreservation is unlikely to affect the therapeutic properties of MSCTRAIL and sup-
ports the generation of a cryopreserved master cell bank.
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Introduction
Mesenchymal stromal cells (MSCs) possess a number
of unique properties that make them attractive can-
didates for cellular based therapies. They are readily
isolated from multiple adult and neonatal tissues and
are easy to expand in ex vivo culture conditions [1].
They secrete a wide range of soluble growth factors
and cytokines that can be immunomodulatory, anti-
apoptotic, anti-inflammatory and anti-fibrotic and can
stimulate repair and regeneration at the site of tissue
injury [2]. In addition to being attracted to sites of
injury, they show evidence of tumor tropism and in-
corporation into the tumour microenvironment [3],
making them ideal vehicles for the delivery of tar-
geted anti-cancer therapies using both systemic and
topical delivery.
These properties have been harnessed further by
genetic modification of MSCs using integrating vectors
[4], resulting in long-term stable gene expression
without affecting the cells critical characteristics [5,6].
Several groups have combined the characteristics of
tumor tropism and long-term genetic modification to
develop targeted anti-cancer therapies [7–11]. In ad-
dition, it seems that MSCs are immunologically inert
because of their low expression of constitutive major
histocompatibility complex 1 (MHC1) and lack of
MHC2 and co-stimulatory molecules CD80, CD86
and CD40, meaning that allogeneic cells can be used
without the need for immunosuppressive therapy in
the recipient [12].
Thus, it is no surprise that there is great interest
in the development of gene and cellular therapies for
the clinic. There are currently more than 500 clini-
cal trials testing MSCs as therapies for a wide range
of diseases, and of these more than 35% are using
cryopreserved cells. From a commercial perspective,
the use of cryopreserved cells has significant
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advantages over fresh cells, including quality control,
standardization of product and the production of an
immediate off-the-shelf therapeutic supply to allow
better timing of therapy. In addition, it is essential to
cryopreserve MSCs at an early passage because many
of their properties decrease with increasing passage.
We have developed a novel targeted genetically
modified MSC therapy for metastatic lung cancer
[7,11,13] and malignant mesothelioma [9] that is un-
dergoing preparation for delivery in a phase 1/2a clinical
trial to patients with metastatic lung cancer.The first
step is the preparation of a master cell bank of allo-
geneic MSCs transduced with a lentiviral vector
expressing tumor necrosis factor–related apoptosis in-
ducing ligand (MSCTRAIL) that will be expanded
to produce a working cell bank and cryopreserved in
a desired concentration until required for delivery to
patients. Cryopreserved allogeneic MSCs have been
used in many previous clinical trials in the treatment
of respiratory disease [14] but more widely in graft-
versus-host disease [15–17] and in cardiac disease for
the treatment of acute myocardial infarction [18] and
ischemic cardiomyopathy [19]. Despite significant ev-
idence of a positive safety profile of these cells, from
an efficacy perspective the trial results have been dis-
appointing with limited therapeutic improvement. One
reason proposed for the lack of clinical efficacy seen
in patients is that cryopreservation of MSCs results
in both apoptosis of cells on thawing and a reduc-
tion in in vitro potency compared with continuously
cultured cells [20–22]. To date the majority of clini-
cal trials using MSCs are doing so to exploit their
immunomodulatory properties, and it has been these
properties that are effected post-cryopreservation. Our
clinical trial is the first to exploit the tumor tropic char-
acteristics of MSCs along with long-term gene
expression, and the effects of cryopreservation on these
has not been assessed.
MSCs for clinical use are commonly frozen in
5–10% dimethyl sulfoxide (DMSO) and fetal bovine
serum (FBS) [2,23,24], but there are disadvantages
of using these agents. DMSO is toxic at high con-
centrations and has been reported to cause adverse
events in patients [25,26], and the use of animal pro-
teins theoretically risks transmitting infectious agents
or stimulating immunological responses. ZENALB 4.5
is a protein supplement obtained from human plasma
that is already in clinical use and would be a suitable
replacement for FBS. In this study, we show that MSCs
can be cryopreserved in 5% DMSO with 95%
ZENALB4.5 without a significant adverse effect on
cell viability, and those cells can be left for up to 90 min
post-thaw without adversely affecting viability.We also
demonstrate for the first time that cryopreservation
does not affect long-term expression of TRAIL and
that there is a minimal reduction in migration of thawed
cells compared with fresh cells. Finally, and most im-
portantly, our thawed cells retain their potency in
causing cancer cell death.
Methods
Chemicals
All chemicals used in this study were purchased from
the Sigma (UK) and culture medium from Invitrogen.
Cell culture
Well-characterized human bone marrow–derived MSCs
(passage 1) were purchased from the Texas A&M
Health Science Center and cultured in α-Minimum
Essential Medium (MEM) containing 17% FBS, 200
units/mL penicillin and streptomycin and L-glutamine.
MSCs were transduced with lentivirus expressing full
lengthTRAIL as previously described [13].The culture
medium for MSCs was changed twice a week. Passage
4 MSC and MSCTRAIL cells were cultured and har-
vested at ~80% confluence using TrypLE (A12859,
Life Technologies) for dissociation and centrifuged.
The harvested passage 5 cells were used for
cryopreservation studies or other assays. Two cancer
cell lines A549 and MDAMB231 (M231) were tested.
M231 is a human breast adenocarcinoma line and
A549 is a human lung adenocarcinoma line. M231
is sensitive to recombinant TRAIL (rTRAIL) treat-
ment, whereas A549 is highly resistant. Both A549 and
M231 were obtained from Cancer Research UK and
grown in Dulbecco’s Modified Eagle’s Medium con-
taining 10% FBS.
Cryopreservation of MSCs
The previously used routine freezing solution (5%
DMSO, 30% FBS in alpha-MEM medium (Gibco-
BRL) was used as a control for cryopreservation study.
The tested freezing solutions were prepared in a human
albumin 4.5% solution (ZENALB 4.5, Bio Products
Laboratory) containing either no DMSO (D0) or in-
creasing concentrations of DMSO (CryoSure-DMSO,
WAK-Chemie Medical) from 0.5% to 20% (D0.5–
D20, respectively). Cells were harvested, washed with
1 × phosphate-buffered saline, then cell pellets direct-
ly resuspended in 1 mL of freezing solution at
concentrations of 1 × 106 cells/mL, 5 × 106 cells/mL
or 10 × 106 cells/mL, transferred into cryovials fol-
lowed by placing the cryovials in an isopropanol
freezing box (Nalgene cryo 1°C/min freezing contain-
er, Nalgene) for overnight freezing in a −80°C freezer
(New Brunswick Scientific), and then stored in liquid
nitrogen vapour (Taylor-Wharton) for at least 1 week
and up to 3 weeks. Before use, the cells were thawed
by rapidly immersing the cryovials in a 37°C water
bath with gentle shaking for 2 min, followed by
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transferring cells into 9 mL of warmed α-MEM for
wash and cells pelleted by centrifugation at 1100 rpm
for 5 min. The pelleted cells were then suspended in
apoptosis assay solution for cell viability assessment
or suspended in culture medium for functionality
analyses.
Cell viability and apoptosis assay
To examine cell viability and apoptosis, cells were de-
frosted as described earlier and left in cell suspension
for 0–150 min, then stained with annexinV-AF647 an-
tibody (Invitrogen) and 4′, 6-diamidino-2-phenylindole
(DAPI; 200 μg/mL; Sigma) and assessed by flow
cytometry. Annexin V+ cells were considered to have
undergone apoptosis; Annexin V+/DAPI+ cells were
considered to be dead by apoptosis; AnnexinV-/DAPI-
cells were considered to be viable.
Co-culture and apoptosis analysis
A549 and M231 cancer cells were labeled with DiI
as previously described [9], 8000 cells were plated into
each well of a 96-well plate and 2000 fresh or
cryopreserved MSCs, or control medium was added
and left for 24 h. Floating and adherent cells were col-
lected, stained with annexin V-AF647 and 2 μg/mL
DAPI (Sigma) and assessed by flow cytometry. As
before, annexin V+ cells were considered to have un-
dergone apoptosis; Annexin V+/DAPI+ cells were
considered to be dead by apoptosis.
Proliferation assay of cryopreserved MSCs
Passage 5 MSCs were thawed, seeded at a density of
10 000 cells per well of a 24-well plate and left to grow
for 6 days. Assessment of cell proliferation was de-
termined every 72 h using the XTT Cell Proliferation
Assay Kit according to the manufacturer’s instructions.
MSC phenotyping and differentiation assay
Cryopreserved MSCs were thawed, washed and cul-
tured for 3 days before phenotyping by using the
human MSC Phenotyping Kit (Miltenyi Biotec, Cat.
No. 130-095-198) according to the manufacturer’s in-
structions. Differentiation of cryopreserved MSCs was
performed by using the StemPro Chondrogenesis, Os-
teogenesis or Adipogenesis Differentiation Kits
(GIBCO Invitrogen Cell Culture). Adipocytes were
stained with HCS LipidTOX TM Green and DAPI,
osteocytes were stained with alizarin red S and the
chondrogenic pellet was stained with alcian blue, all
according to the manufacturer’s instructions. MSCs
cryopreserved by control solution (Cont) and by D5
solution (D5) were both examined for a comparison
of marker protein expression.
Migration assay
MSC migration capacity was assessed usingTranswell
plates (24-well plate format; BD Biosciences) and 8-μm
inserts.The inserts were coated with pure collagen (BD
Biosciences) before seeding 1 × 104 MSCs in 100 μL
per well. The lower chamber was filled with 600 μL
of MDAMB231 conditioned medium as a chemo-
tactic solution. Cells that migrated to the bottom of
the insert were fixed with 4% paraformaldehyde,
stained with DAPI and counted manually using a flu-
orescence microscope (Axioskop2; Zeiss).
Flow cytometry of lentivirus-transduced cells
To determine the effects of cryopreservation on cell
viability, MSCs were stained with annexin V-AF647
and 2 μg/mL DAPI (Sigma) and then assessed by flow
cytometry. For the expression detection of TRAIL or
CXCR4, MSC cells were stained with a phycoery-
thrin (PE)-conjugated mouse mAb (1:10 dilution)
against human TRAIL (Ab47230, Abcam) or a PE
anti-human CXCR4 mAb (Cat. 306506, Biolegend;
1:10 dilution), respectively, and analysed by flow
cytometry.
Statistical analysis
Data were analyzed with the use of GraphPad Prism
6 software (GraphPad Software) and presented as
mean ± SD of at least three separate experiments. Sta-
tistical significance between groups was determined
by use of the Student’s t test for post-thaw cell via-
bility and cancer cell co-culture assessment or
Bonferroni multiple comparison statistic test for mi-
gration assay. Significant probability values are denoted
as *P < 0.05; **P < 0.01; ***P < 0.001.
Results
Cryopreservation of MSCs
To determine the effects of different cryopreservant
combinations on MSC viability cell freezing solu-
tions were prepared as described in Table I. Cell
viability after thawing was assessed by annexin V and
DAPI staining using flow cytometry. Cell viability of
continuously cultured fresh MSCTRAIL was
87.05 ± 1.20% and this was maintained in standard
control cryopreservation media containing 30% FBS,
which gave 85.07 ± 1.25% post-thaw cell viability
(Figure 1A). Compared with fresh cells, the viability
of MSCTRAIL cryopreserved in DMSO-free solu-
tion D0 was significantly reduced to 5.16 ± 0.54% only.
Increasing concentrations of DMSO shows an in-
crease in cell viability compared with no DMSO, up
862 Z.Yuan et al.
Table I. MSC freezing solutions.
Solution
name
FBS
(% v/v)
DMSO
(% v/v)
α-MEM
(% v/v)
4.5% HAS
(% v/v)
Cont 30 5 65 0
D0 0 0 0 100.0
D0.5 0 0.5 0 99.5
D1 0 1.0 0 99.0
D2 0 2.0 0 98.0
D4 0 4.0 0 96.0
D5 0 5.0 0 95.0
D10 0 10.0 0 90.0
D15 0 15.0 0 85.0
D20 0 20 0 80.0
Cont, control freezing solution; D, DMSO; HAS, human albumin 4.5% solution (4.5% W/V solution for infusion human albumin solu-
tion; ZENALB 4.5, Bio Products Laboratory Limited).
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Figure 1. Assessment of post-thaw MSCTRAIL viability by apoptosis assay. (a) Cell viability was determined on continuously cultured
fresh cells and post-thaw cryopreserved cells. Fresh, continuously cultured fresh cells; Cont, cells cryopreserved for 1 week in control routine
freezing solution; D0–D20, cells cryopreserved for 1 week in increasing concentrations of DMSO in 4.5% human albumin 4.5% solution.
Data were presented as mean ± SD of at least three separate experiments. *P < 0.05, **P < 0.01 compared with Cont, respectively, by St-
udent’s t-test. (b) Long-term storage cell viability. MSCTRAILs, cryopreserved in D5 solution for 1 week (1w) or 3 weeks (3w), were
analyzed. (c) MSCTRAILs were cryopreserved in D5 for 1 week, then post-thaw cell viability was determined immediately after thawing
(0 min) or after being left in the thawed D5 solution for 30, 60, 90, 120 or 150 min. *P < 0.05, **P < 0.01 compared with viability at
0 min, respectively, analyzed by Student’s t-test. (d) Post-thaw cell viability for various cryopreservation densities as indicated. Cells were
frozen for 1 week. Cell viability was measured by flow cytometry using AF647-annexin V/DAPI staining. Cells negative for both annexin
V and DAPI were regarded as viable cells.
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to a concentration of 10%. Cell viability in 10%
DMSO and 90% ZENALB 4.5 (88.5 ± 0.71%) was
similar to that of continuously cultured fresh coun-
terpart (87.05 ± 1.02%) and slightly better than in
control cryopreservation solution Cont (85.07 ± 1.25%;
Figure 1a). From a clinical perspective, the total con-
centration of DMSO delivered to patients is important
because high DMSO concentrations can result in
adverse reactions including nausea, headache, hypo-
tension and gastrointestinal upset [25,26].To reduce
this effect, it is important to keep the concentration
of DMSO to a minimum, and our results show that
although there is a slight reduction in cell viability using
5% DMSO (85.65 ± 0.35%) compared with using
10% DMSO containing solution D10 (88.5 ± 0.71%),
this would be worth tolerating to enable a reduction
in DMSO delivery to the patient. Of note, >10% of
DMSO included in the ZENALB 4.5 solution, that
is, 15% and 20% DMSO-containing freezing solu-
tions D15 and D20, cause a significant reduction in
MSC viability (70.6 ± 0.42% and 64.1 ± 0.85%,
respectively).
Because 5% DMSO in ZENALB 4.5 freezing
solution has shown a compatible cell viability pres-
ervation with those frozen in control formulation,
this will be used in the clinical trial setting. For this
reason, all subsequent cells tested were frozen in the
D5 freezing solution. Long-term cryopreservation
storage of MSCTRAIL cells showed that MSCs
cryopreserved in D5 solution showed no change in
post-thaw cell viability for up to at least 3 weeks
(Figure 1b).
In a clinical setting, cryopreserved MSCs
will be rapidly thawed at the patient’s bedside and
immediately delivered by intravenous administra-
tion. It is therefore important to demonstrate the
stability of MSCTRAIL in the cryopreservation media.
We examined post-thaw MSCTRAIL viability after
different incubation periods ranging from 0 to 150 min
by apoptosis assay. Cell viability was 85.65 ± 0.35%
immediately post-thaw, and this viability was main-
tained for up to 90 min (Figure 1c). At 120 min, cells
started to show a significant fall in viability
(82.7 ± 0.85%), which dropped further when
left for 150 min (78.5 ± 0.57).This is relevant because
it gives an indication of the stability of the post-thaw
product and will ensure that protocols can be de-
signed to ensure that infusion of cells occurs within
90 min.
A final consideration regarding an “off-the-shelf”
cryopreserved cell therapy product is the cell density
at which it can be frozen. We tested cell viability of
MSCTRAIL after cryopreservation at cell densities of
1 × 106, 5 × 106 and 1 × 107 and demonstrated no sig-
nificant difference in post-thaw viabilities of
approximately 85% (Figure 1d).
Proliferation, morphology and differentiation of
cryopreserved MSCTRAIL
To determine the effect of cryopreservation on
MSCTRAIL cell proliferation, morphology and dif-
ferentiation, cells were defrosted and their stem cell
characteristics assessed using flow cytometry for known
MSC surface expression markers (CD73, CD90 and
CD105) and differentiation into fat, bone and carti-
lage lineages. An XTT assay was used to determine
whether cryopreservation altered the rate of cell pro-
liferation. Notably, MSCTRAIL frozen in D5 solution
exhibited significantly better proliferation potential than
those cryopreserved with control freezing solution
(Figure 2a). Expression of the characteristic MSC phe-
notypic markers CD105, CD90 and CD73 (Figure 2b)
and lack of expression of the hematopoietic markers
CD14, CD20, CD34 and CD45 (data not shown)
showed no difference between D5 cryopreserved cells
and routinely frozen counterparts in Cont solution.
The differentiation potential of MSCTRAIL frozen
in D5 solution was also examined and shown to be
well preserved, with thawed cells capable of under-
going osteogenic, chondrogenic and adipogenic
differentiation, respectively (Figure 2c). These data
show that cryopreservation of MSCTRAIL in D5 so-
lution does not affect MSC phenotype, proliferation
and differentiation capacities.
Cryopreserved MSCs maintain CXCR4 expression and
cancer-homing ability
The ability of MSCs to home to tumors is one of the
key characteristics we are exploiting in our clinical
therapy and one of the key mediators is CXCR4 [27].
To examine the effect of cryopreservation on CXCR4
expression in MSCs, we stained both fresh and thawed
MSCs and MSCTRAIL cells with a PE-conjugated
anti-human CXCR4 antibody and performed flow
cytometry analyses. The cryopreserved cells showed
equivalent CXCR4 expression levels compared with
fresh cells, suggesting cryopreservation may not change
MSC homing capacity (Figure 3a). To test this pre-
sumption, a three-dimensional collagen gel migration
assay was performed. MSCs and MSCTRAIL, both
fresh and defrosted, demonstrated good migration
ability when chemo-attracted by cancer cell M231 con-
ditioned medium (Figure 3b). Of note, fresh
MSCTRAIL demonstrated significantly higher mi-
gration ability (migrated cell number 676 ± 77) than
their thawed frozen counterparts (migrated number
512 ± 22), suggesting cryopreservation had affected
MSCTRAIL homing potential although their CXCR4
expression not changed. However the effect ap-
peared limited because the migration capacity
of cryopreserved MSCTRAIL (512 ± 22) was
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compatible with that of continuously cultured fresh
MSCs (484 ± 24).This finding demonstrates that the
tumor tropism of MSCs is maintained after
cryopreservation in D5 solution, rationalizing the direct
administration of thawed MSCTRAIL as a targeted
anti-cancer therapy.
Cryopreserved MSCTRAIL cells maintainTRAIL
expression and effectively induce apoptosis in cancer cells
We next assessed cryopreserved and fresh MSCs for
TRAIL expression and their therapeutic ability to
induce apoptosis in cancer cells. Fresh and thawed
MSCTRAIL cells were stained with a PE-anti-
TRAIL antibody and analyzed by flow cytometry.
There was no significant difference in TRAIL expres-
sion following cryopreservation (Figure 4a).To further
confirm the biological activity of TRAIL in thawed
cells, cryopreserved MSCTRAILs were defrosted and
immediately added to DiI-labeled cancer cells at a ratio
of 1:4 (MSCTRAILs: cancer cells) for overnight co-
culture. For a comparison, fresh MSCTRAILs were
also tested in parallel. All cells were stained and ana-
lyzed for apoptosis using annexin-V-AF647 and DAPI
staining by flow cytometry and those that were DiI
positive were assumed to be cancer cells. The breast
adenocarcinoma line MDAMB231 (M231) and the
lung adenocarcinoma line A549 were tested. Al-
though cryopreserved MSCs showed no (A549) or low
induction of apoptosis (M231) in cancer cells com-
pared with no cell control (Figure 4b), both
cryopreserved and fresh MSCTRAIL were equally ef-
fective in the killing of both M231 (45.2 ± 6.7% vs
45.6 ± 5.6% cancer cell death, respectively) and A549
cells (44.2 ± 4.7% and 43.9 ± 3.6%, respectively;
Figure 4b).These observations show that MSCTRAIL
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Figure 2. Cryopreservation does not affect MSC proliferation, marker protein expression and differentiation potential. (a) Post-thaw cell
viability and proliferation were assessed using the XTT assay for 6 days. (b) Phenotyping of cryopreserved MSCTRAIL by detection of
MSC markers. Cryopreserved cells were thawed and cultured for 3 days before phenotyping analyses. (c) Post-thaw MSCTRAIL differ-
entiation capacity was assessed by culturing thawed cells in adipogenic, chondrogenic or osteogenic differentiation media. Left, HCS LipidTOX
Green staining (green) for neutral lipid and DAPI staining for nuclei (blue) to show adipogenic differentiation; middle, alcian blue stain-
ing (blue) to show chondrogenic differentiation; and right, alizarin red S staining (red) to show osteogenic differentiation. Magnification
×200 for adipogenesis assay, ×100 for osteogenesis assay and ×50 for chondrogenesis assay. *P < 0.05, compared with MSCTRAIL/
Control (Cont) growth on days 3 and 6, respectively, analysed by Student’s t-test.
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cryopreserved in D5 solution retains its therapeutic
efficacy.
Discussion
This study is the first to look at the effect of
cryopreservation on the homing ability of both trans-
duced and untransduced MSCs and the stability of
long-term genetic modification.We demonstrate that
MSCTRAIL can be successfully cryopreserved in 5%
DMSO with 95% ZENALB 4.5 without affecting cell
viability, phenotype or differentiation potential. This
is in line with previously published data, although in
these studies, different cryopreservants were used, only
some of which were clinically relevant [20,28,29].Ten
percent DMSO is associated with infusional toxici-
ties in patients receiving cryopreserved cells, the severity
of which is proportional to the amount of DMSO
infused [26], so the ability to reduce the DMSO con-
centration used will have direct patient benefits. In
addition, the removal of FBS from the formulation will
be useful in meeting the current regulatory require-
ments for Good Manufacturing Practice process and
improving safety for patients.
We have previously shown that intravenous deliv-
ery of MSCTRAIL eliminates and reduces lung
metastases [7]. One of the critical steps in translat-
ing these research findings into a realistic therapy for
patients is the development of a cryopreserved master
cell bank that can be further expanded to produce a
working cell bank that will be frozen before delivery
to patients.The success of any treatment is reliant on
cells maintaining their therapeutic properties after
cryopreservation.The majority of clinical trials using
cryopreserved MSCs have been in inflammatory con-
ditions, including chronic obstructive lung disease [14],
acute lung injury [30], graft-versus-host disease [15–17]
and inflammatory bowel disease [31], with variable
results. Thus, there have been a number of studies
looking at the effect of cryopreservation on the se-
cretory and immunomodulatory characteristics of
MSCs, the results of which have been conflicting. Some
studies show that cryopreserved cells have a reduced
ability to suppressT-cell proliferation immediately post-
thaw, which is fully restored after brief culture [21,32],
whereas others show that there is no effect [28,33].
These differences may be explained by the use of dif-
ferent freezing media and the use of FBS during
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Figure 3. Analyses of CXCR4 expression and migration potential in fresh or cryopreserved MSC and MSCTRAIL cells (passage 5). (a)
CXCR4 expression was measured by FACS. Cells were stained by an isotype immunoglobulin G-PE or by an anti-human-CXCR4-PE
antibodies, respectively. (b) Three-dimensional collagen gel migration assay of fresh or cryopreserved MSCs and MSCTRAILs compared
with fresh MSCTRAILs, respectively, analyzed by Bonferroni multiple comparison statistic test (***P < 0.001).
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culturing. For those diseases that require the
immunomodulatory properties of MSCs, it may be that
cells must be cultured for a short time post-
cryopreservation to have a therapeutic effect; with this
step the cost and complexity of the manufacturing
process increases, however.
As yet there is no potency assay for the
immunomodulatory potential of MSCs, making it dif-
ficult to demonstrate whether cell potency and therefore
therapeutic efficacy is affected by freezing. A re-
cently published article comparing the ability of freshly
thawed and continuously cultured MSCs to reduce
allergic airway inflammation in vivo showed that the
two products are equally effective [34]. Because our
product delivers a therapeutic protein, we have an ad-
vantage as we are able to demonstrate effective
induction of cancer cell apoptosis and death via a co-
culture assay. We tested the ability of immediately
thawed MSCTRAIL to kill two adenocarcinoma cell
lines, A549 and M231, and showed that there was no
reduction in TRAIL expression or the cancer cell–
killing potency of our clinical product. Our phase 1/2a
clinical trial is the first to deliver a genetically modi-
fied MSC therapy to lung cancer patients, and these
results suggest that the production and cryopreservation
of both a master and working cell bank is feasible
without affecting the key characteristics required for
therapeutic function.
One of the key features we are relying on in our
therapy is the ability of MSCs to localize at the site
of tumors. MSCs were first demonstrated as homing
to distant sites when they were identified in the bone
marrow of patients with osteogenesis imperfecta after
systemic infusion. Not only did they home, but they
were able to engraft and function resulting in in-
creased growth velocity [35]. Subsequent studies
looking at labeled MSCs suggested that intrave-
nously delivered cells would be identified at high levels
within the lung, liver and spleen but in low levels in
other tissues [36], making the probability of true
homing less likely.The most likely explanation for this
is that MSCs accumulate in the pulmonary capillary
system following intravenous delivery, hence their high
levels soon after administration and interaction with
adhesion molecules, such as vascular cell adhesion mol-
ecule (VCAM), which determines their biodistribution
[37]. Tumors are thought to behave slightly differ-
ently and have been shown to be a target for injected
MSCs [38]. Although the precise mechanism through
which tumors attract MSCs is unclear, there is a con-
sensus that CXCR4 plays a key role via its interaction
with stromal cell–derived factor (SDF)-1 [39] and mac-
rophage migratory inhibitory factor (MIF) [27]. Jarocha
et al. [40] looked at the effect of pre-incubation with
10% DMSO on hematopoietic stem cells (HSCs) and
showed a significant increase in the surface expres-
sion of CXCR4 with an associated enhanced
chemotaxis to an SDF-1 gradient. This also corre-
lated with increased in vivo homing to the bone marrow
of sublethally irradiated mice [40]. However, this study
only looked at the effect of DMSO without
cryopreservation on a different cell type, thus the rel-
evance of this work is not clear. Faint et al. investigated
the effect of cryopreservation on lymphocyte migra-
tion and adhesion and demonstrated no functional
effect but again noted an increased expression of
CXCR4 [41].
Our data shows that in both transduced and
untransduced MSCs, there is no change in CXCR4
expression following cryopreservation. Although this
is not consistent with the previous studies [40,41], it
is likely due to experimental differences. We used a
lower concentration of DMSO (5% compared with
10%), the previous studies both used pre-incubation
of fresh cells rather than complete cryopreservation
and subsequent thaw, and finally, they used different
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Figure 4. Cryopreserved MSCTRAIL maintain TRAIL expres-
sion and cancer cell–killing capacities. (a) Both fresh and post-
thaw MSCs and MSCTRAILs (passage 5) were stained with a PE
conjugated anti-human TRAIL antibody (ab47230) and analyzed
by flow cytometry. (b). Fresh MSCTRAILs or post-thaw MSCs
and MSCTRAILs were co-cultured with cancer cells A549 and
M231 with a cell number ratio of 1:4 (MSC:cancer), respectively,
followed by AF647-AnnexinV antibody and DAPI staining for apop-
tosis assay. *P < 0.05, **P < 0.01 compared with no MSCs condition,
respectively, analyzed by Student’s t-test.
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cell types.We saw a significant reduction in the number
of migrating cells with cryopreserved MSCTRAIL
compared with fresh counterparts; however, the dif-
ference is small, and levels of migration are still good
and equivalent to untransduced cells.
Taken together, the results of our study demon-
strate that both transduced and untransduced MSCs
can be successfully cryopreserved in a combination
of 5% DMSO and 95% ZENALB 4.5 without af-
fecting cell viability or their immunophenotypic and
differentiation properties.This is encouraging from a
clinical perspective because it will reduce the inci-
dence of infusion-related toxicities when delivering the
cell therapy.We have determined a therapeutic window
post-thaw that will enable us to accurately deter-
mine the duration of MSCTRAIL infusion without
a loss of cell viability.We have also demonstrated for
the first time that CXCR4 expression is not altered
following cryopreservation in either transduced or
untransduced cells and that although there is a re-
duction in cell migration, there is no reduction in
TRAIL transgene expression or cancer cell killing ef-
ficacy. This suggests that we can safely produce a
cryopreserved MSCTRAIL product that can be sub-
sequently delivered to the patient in a clinical trial
setting without a reduction in therapeutic efficacy and
in a timely and cost-effective manner.
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